KNTE News and Press, Kinnate Biopharma Inc. From 04/17/23

Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor types and BRAF or NRAS alterations with a total of 8 partial responses in the monoth...

2023-04-14 13:00:16 ET Gainers: SAI.TECH Global Corporation ( SAI ) +166% . CXApp ( CXAI ) +80% . Oblong ( OBLG ) +88% . Allarity Therapeutics ( ALLR ) +57% . Marpai ( MRAI ) +33% . Eightco Holdings ( OCTO ) +34% . ...

2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...

2023-03-15 17:08:20 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): FY GAAP EPS of -$2.64 in-line. As of December 31, 2022, the total of cash and cash equivalents and investments was $266.3 million, inclusive of cash from Kinnjiu Biopharma Inc., and is expected to fun...

Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual Meeting Announced the company has initiated enrollment of patients into ...

Company has initiated enrollment of patients into the monotherapy expansion cohorts Company to host a virtual investor webcast on April 17, 2023, to discuss the AACR results and dose expansion strategy, and to provide additional pipeline updates SAN FRANCISCO and SAN DIEGO, ...

Summary Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront and up to $1.1 billion in milestones. The $937 million agreement between Beijing InnoCare and Biog...

Kinnate Biopharma ( NASDAQ: KNTE ) said it acquired ownership stake in its China joint venture (JV) Kinnjiu Biopharma which was held by Series A investors using a combination of Kinnate shares and cash. Kinnjiu was formed in 2021 as part of Kinnate's JV to develop and sell its mo...

Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structure Kinnate’s cash runway still expected to fund current operations into mid-2024 Trial sites open in People's Republic of China (PRC) and...

Kinnate Biopharma ( NASDAQ: KNTE ) on Tuesday said the U.S. Food and Drug Administration (FDA) had granted a fast track designation to its inhibitor KIN-3248 for the treatment of bile duct cancer. The FDA granted the designation to KIN-3248 for the treatment of patients with unres...